Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes.

More search options...

Gill, D; Burgess, S (2020) Use of a Genetic Variant Related to Circulating FXa (Activated Factor X) Levels to Proxy the Effect of FXa Inhibition on Cardiovascular Outcomes. Circ Genom Precis Med, 13 (5). pp. 551-553. ISSN 2574-8300 https://doi.org/10.1161/CIRCGEN.120.003061
SGUL Authors: Gill, Dipender Preet Singh

Preview

PDF Published Version
Available under License Creative Commons Attribution.
Download (175kB) | Preview

Item Type:

Article

Additional Information:

© 2020 The Authors. Circulation: Genomic and Precision Medicine is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Keywords:

Mendelian randomization analysis, cardiovascular disease, coronary artery disease, serine protease

SGUL Research Institute / Research Centre:

Academic Structure > Infection and Immunity Research Institute (INII)

Journal or Publication Title:

Circ Genom Precis Med

ISSN:

2574-8300

Language:

eng

Dates:

Date	Event
October 2020	Published
13 August 2020	Published Online
1 July 2020	Accepted

Publisher License:

Creative Commons: Attribution 4.0

Projects:

Project ID	Funder	Funder ID
203928/Z/16/Z	Wellcome Trust	http://dx.doi.org/10.13039/100004440
RE/18/4/34215	British Heart Foundation	http://dx.doi.org/10.13039/501100000274
204623/Z/16/Z	Wellcome Trust	http://dx.doi.org/10.13039/100004440